Response of patients treated with caplacizumab as initial treatment vs patients not treated with caplacizumab in terms of number of PEX, days of hospitalization, and days in the intensive care unit
| . | patients with iTTP treated with caplacizumab as initial treatment . | patients with iTTP not treated with caplacizumab . | P . |
|---|---|---|---|
| No. of PEX | |||
| N | 44 | 76 | .017 |
| Mean ± SD | 12.39 ± 11.8 | 18.51 ± 19.05 | |
| Median (IQR) | 8.5 (6-12.5) | 14 (7-21.5) | |
| Days of hospitalization | |||
| N | 44 | 51 | .001 |
| Mean ± SD | 14.68 ± 12.36 | 21.94 ± 14.42 | |
| Median (IQR) | 12 (9-15) | 19 (12-27) | |
| Days in ICU | |||
| N | 42 | 71 | .796 |
| Mean ± SD | 2.31 ± 2.62 | 2.79 ± 3.51 | |
| Median (IQR) | 2 (0-4) | 2 (0-4) | |
| . | patients with iTTP treated with caplacizumab as initial treatment . | patients with iTTP not treated with caplacizumab . | P . |
|---|---|---|---|
| No. of PEX | |||
| N | 44 | 76 | .017 |
| Mean ± SD | 12.39 ± 11.8 | 18.51 ± 19.05 | |
| Median (IQR) | 8.5 (6-12.5) | 14 (7-21.5) | |
| Days of hospitalization | |||
| N | 44 | 51 | .001 |
| Mean ± SD | 14.68 ± 12.36 | 21.94 ± 14.42 | |
| Median (IQR) | 12 (9-15) | 19 (12-27) | |
| Days in ICU | |||
| N | 42 | 71 | .796 |
| Mean ± SD | 2.31 ± 2.62 | 2.79 ± 3.51 | |
| Median (IQR) | 2 (0-4) | 2 (0-4) | |
ICU, intensive care unit; SD, standard deviation.